A Phase 1/2 Dose Escalation Study Evaluating Safety and Feasibility of BPX-501 T Cells After Partially Mismatched, Related, T Cell-Depleted HSCT (Hematopoietic Stem Cell Transplant)
Phase of Trial: Phase I/II
Latest Information Update: 03 Apr 2017
At a glance
- Drugs Rivogenlecleucel (Primary) ; Rimiducid
- Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Graft-versus-host disease; Lymphoma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Sponsors Bellicum Pharmaceuticals
- 27 Mar 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Jun 2017.
- 25 Mar 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2018 as per ClinicalTrials.gov record.
- 25 Mar 2016 Planned primary completion date changed from 1 Jan 2015 to 1 Jan 2017 as per ClinicalTrials.gov record.